JP2021522211A5 - - Google Patents
Info
- Publication number
- JP2021522211A5 JP2021522211A5 JP2020558435A JP2020558435A JP2021522211A5 JP 2021522211 A5 JP2021522211 A5 JP 2021522211A5 JP 2020558435 A JP2020558435 A JP 2020558435A JP 2020558435 A JP2020558435 A JP 2020558435A JP 2021522211 A5 JP2021522211 A5 JP 2021522211A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- carbon atoms
- alkoxy
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023167782A JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658494P | 2018-04-16 | 2018-04-16 | |
| US62/658,494 | 2018-04-16 | ||
| US201862737219P | 2018-09-27 | 2018-09-27 | |
| US62/737,219 | 2018-09-27 | ||
| PCT/US2019/027603 WO2019204257A1 (en) | 2018-04-16 | 2019-04-16 | Ep4 inhibitors and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023167782A Division JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522211A JP2021522211A (ja) | 2021-08-30 |
| JP2021522211A5 true JP2021522211A5 (https=) | 2022-04-25 |
Family
ID=66589884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558435A Pending JP2021522211A (ja) | 2018-04-16 | 2019-04-16 | Ｅｐ４阻害剤およびその使用 |
| JP2023167782A Pending JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023167782A Pending JP2023165946A (ja) | 2018-04-16 | 2023-09-28 | Ｅｐ４阻害剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10973834B2 (https=) |
| EP (1) | EP3781162A1 (https=) |
| JP (2) | JP2021522211A (https=) |
| CN (1) | CN112292128A (https=) |
| AU (1) | AU2019255196A1 (https=) |
| CA (1) | CA3096546A1 (https=) |
| WO (1) | WO2019204257A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021522211A (ja) | 2018-04-16 | 2021-08-30 | アリーズ セラピューティクス， インコーポレイテッド | Ｅｐ４阻害剤およびその使用 |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| MX2021003904A (es) | 2018-10-05 | 2021-10-26 | Annapurna Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. |
| EP3722319A1 (en) * | 2019-04-09 | 2020-10-14 | Rottapharm Biotech S.r.l. | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
| CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
| WO2021226162A1 (en) * | 2020-05-05 | 2021-11-11 | Arrys Therapeutics, Inc. | Ep4 antagonists and their use in the treatment of proliferative diseases |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| EP4215214A4 (en) * | 2020-09-16 | 2024-07-03 | Osaka University | THERAPEUTIC AGENT AGAINST CANCER, IMMUNOSTIMULANT AND SCREENING METHOD FOR ANTI-CANCER SUBSTANCE |
| CN114907267A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 用于抗肿瘤的药物组合 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN2001000224A (es) * | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| KR100747401B1 (ko) | 2003-09-03 | 2007-08-08 | 화이자 인코포레이티드 | 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물 |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| CA2600510C (en) | 2005-03-11 | 2010-11-02 | Pfizer Inc. | Crystal forms of an imidazole derivative |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| WO2009156652A1 (fr) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Structure en nid d'abeille a base de titanate d'aluminium |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2965756B1 (en) * | 2009-04-22 | 2018-10-10 | AskAt Inc. | Selective ep4 receptor antagonistic substance for treatment of cancer |
| JP5594754B2 (ja) | 2009-07-13 | 2014-09-24 | 国立大学法人 東京大学 | 運行実績を活用したオンデマンドバスの運行スケジューリングシステム及びその方法 |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| US9457084B2 (en) | 2010-02-22 | 2016-10-04 | Raqualia Pharma Inc. | Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| CA2907049C (en) | 2013-03-19 | 2021-08-10 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of cartilage disease |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| CN107759590A (zh) | 2014-03-06 | 2018-03-06 | 阿莱塔纳治疗学股份有限公司 | Grapiprant的结晶形式 |
| AU2015264102C1 (en) * | 2014-05-23 | 2020-10-08 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of cancer |
| UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| PT3482760T (pt) * | 2016-07-07 | 2021-12-15 | Ono Pharmaceutical Co | Combinação compreendendo antagonista de ep4 e inibidor de ponto de verificação imunitário |
| US10342785B2 (en) * | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| US20190365680A1 (en) | 2016-11-04 | 2019-12-05 | Askat Inc. | Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer |
| JP2021522211A (ja) * | 2018-04-16 | 2021-08-30 | アリーズ セラピューティクス， インコーポレイテッド | Ｅｐ４阻害剤およびその使用 |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US20210300921A1 (en) | 2018-07-11 | 2021-09-30 | Arrys Therapeutics, Inc. | Ep4 inhibitors and synthesis thereof |
| EP3856177A4 (en) | 2018-09-27 | 2022-06-29 | Arrys Therapeutics, Inc. | Grapiprant unit dosage forms |
| CN115697317A (zh) * | 2020-04-08 | 2023-02-03 | 株式会社AskAt | Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用 |
-
2019
- 2019-04-16 JP JP2020558435A patent/JP2021522211A/ja active Pending
- 2019-04-16 CN CN201980033839.6A patent/CN112292128A/zh active Pending
- 2019-04-16 EP EP19724972.5A patent/EP3781162A1/en not_active Withdrawn
- 2019-04-16 CA CA3096546A patent/CA3096546A1/en active Pending
- 2019-04-16 US US16/385,524 patent/US10973834B2/en active Active
- 2019-04-16 WO PCT/US2019/027603 patent/WO2019204257A1/en not_active Ceased
- 2019-04-16 AU AU2019255196A patent/AU2019255196A1/en not_active Abandoned
-
2021
- 2021-03-01 US US17/187,900 patent/US20210290641A1/en not_active Abandoned
-
2023
- 2023-07-19 US US18/355,232 patent/US20240066040A1/en not_active Abandoned
- 2023-09-28 JP JP2023167782A patent/JP2023165946A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522211A5 (https=) | ||
| Kwapisz | Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib | |
| Jhaveri et al. | A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer | |
| RU2597844C2 (ru) | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака | |
| JP6640288B2 (ja) | 卵巣癌の治療のための併用療法 | |
| O’Sullivan | Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors | |
| JP2015532292A5 (https=) | ||
| Polk et al. | Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence | |
| Leung et al. | Potentiation of growth inhibitory responses of the mTOR inhibitor everolimus by dual mTORC1/2 inhibitors in cultured breast cancer cell lines | |
| RU2018111439A (ru) | Новое пиразоло[3, 4-d]пиримидиновое соединение или его соль | |
| MX2014011925A (es) | Dosificacion y administracion de anticuerpos monoespecíficos y biespecíficos anti- igf 1r y anti erbb3. | |
| MX2011000440A (es) | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. | |
| JP2013531069A (ja) | ４−ヨード−３−ニトロベンズアミド及びイリノテカンを用いる転移性乳癌の治療方法 | |
| JP2011121944A5 (https=) | ||
| KR20150038593A (ko) | 교모세포종의 치료를 위한 조합 요법 | |
| WO2013138371A1 (en) | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody | |
| JP2014533277A5 (https=) | ||
| TN2012000493A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| US20160303232A1 (en) | Combination treatments with seribantumab | |
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ | |
| D Husseinzadeh et al. | Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma | |
| Martino et al. | Selinexor in multiple myeloma | |
| Juengel et al. | Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells | |
| KR20260018865A (ko) | Kras-의존성 암 치료용 파네실트랜스퍼라제 억제제 | |
| Wang et al. | AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes |